What percentage of patients achieved clinical cure with Vigamox at days 5-6?

Vigamox, a topical antibiotic used to treat bacterial conjunctivitis, has been studied to evaluate its efficacy in achieving clinical cure among patients. The range of 66-69% represents the percentage of patients who experienced a complete resolution of their symptoms and signs associated with the infection within five to six days of treatment.

This percentage aligns with the results typically observed in clinical trials for Vigamox, where a significant proportion of patients show improvement or resolution of symptoms within the early treatment period. The specific range of 66-69% captures the effective outcomes consistently reported, making it a suitable and accurate representation of the efficacy of Vigamox in curing the condition within the specified timeframe.

The other ranges do not match reported clinical outcomes as closely and may suggest a misunderstanding of the trial data associated with Vigamox. Focusing on the demonstrated clinical cure rates derived from studies helps clarify the expected effectiveness of the antibiotic in treating bacterial eye infections.